Genprex
NASDAQ: GNPXAustin, US · Texas corporation
Find your way into Genprex
48 people in our graph share verified history with the Genprex team — schools, employers, funds. One of them is your warm intro.
Kevin Crowderunlockedknows Rodney Varner · together at Texas A&M University (overlapped)
×2knows the team · via Texas A&M University
×9knows the team · via The University of Texas School of Law
Genprex is a clinical-stage gene therapy company developing treatments for cancer and diabetes, including approaches that reintroduce tumor suppressor genes and stabilize glucose levels. Its therapies have received multiple FDA Fast Track Designations and are being evaluated in clinical trials.
Founders & leadership
JR
John Rodney VarnerCo-founder
RV
Rodney VarnerinFounderRodney Varner is co-founder, Chairman, and CEO of Genprex (Nasdaq: GNPX), a clinical-stage gene therapy company developing treatments for cancer and diabetes.
RM
Ryan M. ConferinPresident, Chief Executive Officer, & DirectorRyan Confer serves as President, Chief Executive Officer, and Chief Financial Officer of Genprex, a clinical-stage gene therapy company. His career has focused on identifying emerging technologies in academic and laboratory settings and translating them into commercial applications, with experience investing in and developing companies across SaaS, medical devices, fintech, and industrial design.
MS
Mark S. BergerinChief Medical OfficerMark S. Berger is Chief Medical Officer at Genprex, a gene therapy company developing treatments for cancer and diabetes. He has over 25 years of experience in oncology drug development across large pharmaceutical and biotech companies, including leadership roles at GlaxoSmithKline, Wyeth Research, Deciphera Pharmaceuticals, Kadmon, and Actinium Pharmaceuticals, where he contributed to the development and approval of multiple therapeutics including Tykerb and Mylotarg.
Board
BP
Bob PearsonBoard director
DF
David FriedmanBoard director
Reported raises · per SEC filings
Form D private placements$11.1M disclosed across 3 of 8 rounds · 1900–2019
▶$1.5MofferedNov 2019 · 2 investors · BiotechnologyRule 506(b)
▶$1.5MofferedNov 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert W. PearsonDirector
- David E. FriedmanDirector
- Julien PhamExecutive Officer
- Ryan M. ConferExecutive Officer
- John Rodney VarnerExecutive Officer, Director
- Offering amount
- $1.5M
- Sales commissions
- $88.7K
- Placement agents
- Joseph Gunnar & Co., LLC
- First sale
- Nov 2019
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$10MraisedMay 2018 · 2 investors · BiotechnologyRule 506(b)
▶$10MraisedMay 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Julien PhamExecutive Officer
- John Rodney VarnerExecutive Officer, Director
- David FriedmanDirector
- Robert PearsonDirector
- Ryan ConferExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $700K
- Placement agents
- Maxim Group LLC
- First sale
- May 2018
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$950KraisedOct 2016 · 1 investors · BiotechnologyRule 506(b)
▶$950KraisedOct 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ryan ConferExecutive Officer
- David FriedmanDirector
- John Rodney VarnerExecutive Officer, Director
- Bob PearsonDirector
- Amount sold
- $950K
- Minimum investment
- $25K
- Sales commissions
- $47.2K
- Placement agents
- Network 1 Financial Securities, Inc.
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 05, 06b, 4a5
▶$160KraisedMar 2015 · 1 investors · BiotechnologyRule 506(b)
▶$160KraisedMar 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bob PearsonDirector
- David FriedmanDirector
- John Rodney VarnerExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $160K
- Minimum investment
- $20K
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 05, 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$75.9Mvaluation at IPOOct 2017 · $5.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 5
by search overlap
Robinhood25 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits24 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
TradingView19 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Perplexity19 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Quiverquant18 shared keywordsQuiver Quantitative scrapes and aggregates alternative stock market data from across the internet into a free web dashboard. It targets retail investors, giving non-professional traders access to alternative data typically reserved for institutional money managers.
Companies competing with Genprex for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Genprex posts Q2 2026 results and cash runway update | GNPX Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Genprex do?
- Genprex is a clinical-stage gene therapy company developing treatments for cancer and diabetes, including approaches that reintroduce tumor suppressor genes and stabilize glucose levels. Its therapies have received multiple FDA Fast Track Designations and are being evaluated in clinical trials.
- Who founded Genprex?
- Genprex was founded by John Rodney Varner, Rodney Varner.
- How much funding has Genprex raised?
- Genprex has disclosed $11.1M raised across 3 of its 8 known rounds.
- Where is Genprex headquartered?
- Genprex is headquartered in Austin, US.